+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cancer/Tumor Profiling Market by Technology (Conventional PCR, Digital PCR, FISH), Product Type (Consumables Reagents, Instruments, Software & Services), Application, End User - Global Forecast 2025-2030- Product Image
Cancer/Tumor Profiling Market by Technology (Conventional PCR, Digital PCR, FISH), Product Type (Consumables Reagents, Instruments, Software & Services), Application, End User - Global Forecast 2025-2030- Product Image
Sale

Cancer/Tumor Profiling Market by Technology (Conventional PCR, Digital PCR, FISH), Product Type (Consumables Reagents, Instruments, Software & Services), Application, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 180 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5592101
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The cancer/tumor profiling market is undergoing a rapid transformation, propelled by advancements in molecular diagnostics and an increasing emphasis on precision medicine in oncology. Senior leaders are seeking actionable intelligence to guide investment, partnership, and technology adoption decisions within this dynamic global sector.

Market Snapshot: Cancer/Tumor Profiling Market Growth and Opportunity

The cancer/tumor profiling market grew from USD 12.77 billion in 2024 to USD 15.29 billion in 2025. It is expected to continue growing at a CAGR of 18.86%, reaching USD 36.01 billion by 2030. Significant expansion is driven by innovation in molecular analysis, regulatory support for precision diagnostics, and the escalating demand for tailored therapies in oncology. The landscape features intense competition among leading providers aligning advanced platforms with evolving clinical and operational priorities.

Cancer/Tumor Profiling Market: Scope & Segmentation

This report provides a comprehensive analysis of technology adoption, product types, applications, end users, regions, and company activities in cancer/tumor profiling.

  • Technology: Conventional PCR, Digital PCR, Fluorescence In Situ Hybridization, Immunohistochemistry, Microarray, Next Generation Sequencing (including targeted, transcriptome, exome, and genome sequencing), Real-Time PCR.
  • Product Type: Consumables and reagents (antibodies, PCR reagents, probes, sequencing reagents), Instruments (fluorescence microscopes, mass spectrometers, microarray scanners, PCR instruments, sequencers), Software and services (bioinformatics, cloud platforms, data management, consultation).
  • Application: Profiling for breast, colorectal, lung, and prostate cancers, including gene expression, mutation detection, epigenetic, proteomic, and receptor analyses.
  • End User: Clinical and reference laboratories, oncology departments, pathology labs, clinical trial units, pharmaceutical and biopharma companies, research centers, government and academic labs.
  • Region: Americas (notably United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including UK, Germany, France, Russia, Italy, Spain, various EMEA countries), Asia-Pacific (China, India, Japan, Australia, South Korea, Southeast Asian economies).
  • Company Coverage: Analysis includes Thermo Fisher Scientific Inc., Illumina, Inc., F. Hoffmann-La Roche Ltd, QIAGEN N.V., Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., PerkinElmer, Inc., Guardant Health, Inc., Natera, Inc., and NeoGenomics, Inc.

Key Takeaways: Strategic Insights Shaping the Tumor Profiling Landscape

  • Ongoing convergence of genomic science and oncology drives the adoption of advanced tumor profiling for more precise cancer diagnostics and personalized treatments.
  • Integration of high-throughput sequencing, digital PCR, and robust bioinformatics streamlines laboratory workflows, enhances confidence in diagnostic results, and supports faster clinical decision making.
  • Market leaders are prioritizing end-to-end platforms that combine validated instruments, intuitive software, and reliable reagent supply to improve user experience and outcome delivery.
  • Collaborative alliances with biopharma and technology developers expedite the rollout of companion diagnostics, bringing new profiling applications from research into real-world clinical use more efficiently.
  • Innovations in sample preparation, multi-omics integration, and assay automation are reshaping operational models in both developed and emerging regions, resulting in broader access and improved cost control.
  • Regulatory and reimbursement frameworks continue to evolve, supporting translation of profiling innovations into routine cancer care.

Impact of United States Tariff Policies on Tumor Profiling Supply Chains

Newly enacted 2025 United States tariffs have increased the cost of importing reagents, consumables, and instrumentation, prompting diagnostic providers and instrument manufacturers to reassess supplier agreements. Companies are mitigating risks by regionalizing production, forming joint ventures with local manufacturers, and innovating in packaging and inventory management to protect margins. These shifts reinforce the need for strategic sourcing and supply chain flexibility in a global market shaped by regulatory and geopolitical fluidity.

Methodology & Data Sources

Findings are based on in-depth interviews with senior stakeholders in diagnostic laboratories, oncology clinics, and procurement, complemented by peer-reviewed literature, patent and regulatory filings, and company presentations. Data was validated through triangulation and proprietary analytical models, ensuring consistency and reliability across diverse tumor profiling technologies and applications.

Why This Report Matters

  • Senior decision-makers gain an actionable, segmented view of growth drivers, competitive dynamics, and innovation adoption across the tumor profiling market.
  • The report offers a regional breakdown of emerging trends, stakeholder priorities, and evolving operational models, supporting global and local strategy formulation.
  • Analysis of tariff and policy shifts equips leadership with the intelligence needed to anticipate risks and optimize supply networks.

Conclusion

Tumor profiling continues to evolve as a strategic driver of personalized oncology, shaped by technology innovation, regulatory realignment, and the growing importance of integrated, patient-centric solutions. Stakeholders equipped with robust market intelligence are poised to capture emerging opportunities and sustain growth in this vital sector.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Integration of multi-omic profiling techniques combined with AI-driven analytics in personalized oncology treatment planning
5.2. Expansion of liquid biopsy assays enabling non-invasive detection and monitoring of tumor-specific genetic alterations in real time
5.3. Adoption of single-cell sequencing platforms to uncover intratumoral heterogeneity and identify novel therapeutic targets
5.4. Emergence of digital pathology coupled with deep learning algorithms for automated tumor morphology and biomarker quantification
5.5. Development of comprehensive companion diagnostics for targeted therapy selection based on complex genomic signatures
5.6. Growth of decentralized testing workflows incorporating remote sample collection and telemedicine-supported tumor profiling services
5.7. Advances in immunoprofiling technologies for predicting patient response to checkpoint inhibitors and cellular therapies
5.8. Implementation of real-world evidence from population-based registries to refine tumor profiling utility in clinical practice
5.9. Regulatory harmonization efforts aimed at streamlining global approval pathways for advanced tumor profiling assays
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Cancer/Tumor Profiling Market, by Technology
8.1. Introduction
8.2. Conventional PCR
8.3. Digital PCR
8.4. FISH
8.4.1. Chromosome Enumeration Probes
8.4.2. Copy Number Variation
8.4.3. Fusion Gene Detection
8.5. IHC
8.5.1. Direct IHC
8.5.2. Indirect IHC
8.5.3. Tissue Microarray
8.6. Microarray
8.6.1. Comparative Genomic Hybridization
8.6.2. Expression Profiling
8.6.3. SNP Genotyping
8.7. Next Generation Sequencing
8.7.1. Targeted Sequencing
8.7.1.1. Amplicon Based
8.7.1.2. Hybrid Capture
8.7.2. Transcriptome Sequencing
8.7.3. Whole Exome Sequencing
8.7.4. Whole Genome Sequencing
8.8. Real Time PCR
8.8.1. Dye Based
8.8.2. Probe Based
9. Cancer/Tumor Profiling Market, by Product Type
9.1. Introduction
9.2. Consumables Reagents
9.2.1. Antibodies
9.2.2. PCR Reagents
9.2.3. Probes
9.2.4. Sequencing Reagents
9.3. Instruments
9.3.1. Fluorescence Microscopes
9.3.2. Mass Spectrometers
9.3.3. Microarray Scanners
9.3.4. PCR Instruments
9.3.5. Sequencers
9.4. Software & Services
9.4.1. Bioinformatics Software
9.4.2. Cloud Platforms
9.4.3. Consultation Services
9.4.4. Data Management Systems
10. Cancer/Tumor Profiling Market, by Application
10.1. Introduction
10.2. Breast Cancer
10.2.1. Gene Expression Profiling
10.2.2. Genetic Mutation Detection
10.2.3. Proteomic Profiling
10.2.4. Receptor Profiling
10.3. Colorectal Cancer
10.3.1. Epigenetic Profiling
10.3.2. MSI Testing
10.3.3. Mutation Analysis
10.4. Lung Cancer
10.4.1. Minimal Residual Disease Monitoring
10.4.2. Molecular Susceptibility Testing
10.4.3. Therapy Selection
10.5. Prostate Cancer
10.5.1. Copy Number Variation Analysis
10.5.2. Fusion Detection
10.5.3. Gene Expression Analysis
11. Cancer/Tumor Profiling Market, by End User
11.1. Introduction
11.2. Diagnostic Laboratories
11.2.1. Clinical Laboratories
11.2.2. Reference Laboratories
11.3. Hospitals Clinics
11.3.1. Oncology Departments
11.3.2. Pathology Labs
11.4. Pharma & Biopharma Companies
11.4.1. Clinical Trial Units
11.4.2. Companion Diagnostic Services
11.4.3. Drug Development Divisions
11.5. Research & Academic Institutes
11.5.1. Biotech Research Centers
11.5.2. Government Research Institutes
11.5.3. University Research Labs
12. Americas Cancer/Tumor Profiling Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Cancer/Tumor Profiling Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Cancer/Tumor Profiling Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Thermo Fisher Scientific Inc.
15.3.2. Illumina, Inc.
15.3.3. F. Hoffmann-La Roche Ltd
15.3.4. QIAGEN N.V.
15.3.5. Agilent Technologies, Inc.
15.3.6. Bio-Rad Laboratories, Inc.
15.3.7. PerkinElmer, Inc.
15.3.8. Guardant Health, Inc.
15.3.9. Natera, Inc.
15.3.10. NeoGenomics, Inc.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. CANCER/TUMOR PROFILING MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 6. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. CANCER/TUMOR PROFILING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. CANCER/TUMOR PROFILING MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. CANCER/TUMOR PROFILING MARKET: RESEARCHAI
FIGURE 24. CANCER/TUMOR PROFILING MARKET: RESEARCHSTATISTICS
FIGURE 25. CANCER/TUMOR PROFILING MARKET: RESEARCHCONTACTS
FIGURE 26. CANCER/TUMOR PROFILING MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. CANCER/TUMOR PROFILING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CONVENTIONAL PCR, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CONVENTIONAL PCR, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY FISH, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY FISH, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CHROMOSOME ENUMERATION PROBES, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CHROMOSOME ENUMERATION PROBES, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COPY NUMBER VARIATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COPY NUMBER VARIATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY FUSION GENE DETECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY FUSION GENE DETECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY FISH, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY FISH, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY IHC, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY IHC, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DIRECT IHC, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DIRECT IHC, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY INDIRECT IHC, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY INDIRECT IHC, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TISSUE MICROARRAY, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TISSUE MICROARRAY, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY IHC, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY IHC, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAY, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY EXPRESSION PROFILING, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY EXPRESSION PROFILING, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SNP GENOTYPING, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SNP GENOTYPING, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAY, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAY, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY AMPLICON BASED, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY AMPLICON BASED, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY HYBRID CAPTURE, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY HYBRID CAPTURE, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TARGETED SEQUENCING, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TARGETED SEQUENCING, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TRANSCRIPTOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TRANSCRIPTOME SEQUENCING, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REAL TIME PCR, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DYE BASED, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DYE BASED, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROBE BASED, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROBE BASED, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REAL TIME PCR, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REAL TIME PCR, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PCR REAGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PCR REAGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROBES, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROBES, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SEQUENCING REAGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SEQUENCING REAGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY FLUORESCENCE MICROSCOPES, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY FLUORESCENCE MICROSCOPES, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MASS SPECTROMETERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MASS SPECTROMETERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAY SCANNERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAY SCANNERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PCR INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PCR INSTRUMENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SEQUENCERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SEQUENCERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOINFORMATICS SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOINFORMATICS SOFTWARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CLOUD PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CLOUD PLATFORMS, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CONSULTATION SERVICES, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CONSULTATION SERVICES, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DATA MANAGEMENT SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DATA MANAGEMENT SYSTEMS, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GENE EXPRESSION PROFILING, BY REGION, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GENE EXPRESSION PROFILING, BY REGION, 2025-2030 (USD MILLION)
TABLE 117. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GENETIC MUTATION DETECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GENETIC MUTATION DETECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 119. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROTEOMIC PROFILING, BY REGION, 2018-2024 (USD MILLION)
TABLE 120. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROTEOMIC PROFILING, BY REGION, 2025-2030 (USD MILLION)
TABLE 121. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY RECEPTOR PROFILING, BY REGION, 2018-2024 (USD MILLION)
TABLE 122. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY RECEPTOR PROFILING, BY REGION, 2025-2030 (USD MILLION)
TABLE 123. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 124. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 125. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 126. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 127. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY EPIGENETIC PROFILING, BY REGION, 2018-2024 (USD MILLION)
TABLE 128. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY EPIGENETIC PROFILING, BY REGION, 2025-2030 (USD MILLION)
TABLE 129. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MSI TESTING, BY REGION, 2018-2024 (USD MILLION)
TABLE 130. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MSI TESTING, BY REGION, 2025-2030 (USD MILLION)
TABLE 131. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MUTATION ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 132. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MUTATION ANALYSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 133. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COLORECTAL CANCER, 2018-2024 (USD MILLION)
TABLE 134. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COLORECTAL CANCER, 2025-2030 (USD MILLION)
TABLE 135. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 136. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 137. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MINIMAL RESIDUAL DISEASE MONITORING, BY REGION, 2018-2024 (USD MILLION)
TABLE 138. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MINIMAL RESIDUAL DISEASE MONITORING, BY REGION, 2025-2030 (USD MILLION)
TABLE 139. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MOLECULAR SUSCEPTIBILITY TESTING, BY REGION, 2018-2024 (USD MILLION)
TABLE 140. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MOLECULAR SUSCEPTIBILITY TESTING, BY REGION, 2025-2030 (USD MILLION)
TABLE 141. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY THERAPY SELECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 142. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY THERAPY SELECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 143. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 144. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 145. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 146. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 147. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COPY NUMBER VARIATION ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 148. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COPY NUMBER VARIATION ANALYSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 149. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY FUSION DETECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 150. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY FUSION DETECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 151. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GENE EXPRESSION ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 152. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GENE EXPRESSION ANALYSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 153. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 154. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 155. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 156. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 157. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 158. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 159. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 160. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 161. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 162. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 163. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
TABLE 164. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2030 (USD MILLION)
TABLE 165. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY HOSPITALS CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 166. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY HOSPITALS CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 167. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY ONCOLOGY DEPARTMENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 168. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY ONCOLOGY DEPARTMENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 169. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PATHOLOGY LABS, BY REGION, 2018-2024 (USD MILLION)
TABLE 170. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PATHOLOGY LABS, BY REGION, 2025-2030 (USD MILLION)
TABLE 171. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY HOSPITALS CLINICS, 2018-2024 (USD MILLION)
TABLE 172. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY HOSPITALS CLINICS, 2025-2030 (USD MILLION)
TABLE 173. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PHARMA & BIOPHARMA COMPANIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 174. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PHARMA & BIOPHARMA COMPANIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 175. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CLINICAL TRIAL UNITS, BY REGION, 2018-2024 (USD MILLION)
TABLE 176. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CLINICAL TRIAL UNITS, BY REGION, 2025-2030 (USD MILLION)
TABLE 177. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COMPANION DIAGNOSTIC SERVICES, BY REGION, 2018-2024 (USD MILLION)
TABLE 178. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COMPANION DIAGNOSTIC SERVICES, BY REGION, 2025-2030 (USD MILLION)
TABLE 179. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DRUG DEVELOPMENT DIVISIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 180. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DRUG DEVELOPMENT DIVISIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 181. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PHARMA & BIOPHARMA COMPANIES, 2018-2024 (USD MILLION)
TABLE 182. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PHARMA & BIOPHARMA COMPANIES, 2025-2030 (USD MILLION)
TABLE 183. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 184. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 185. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOTECH RESEARCH CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 186. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOTECH RESEARCH CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 187. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 188. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 189. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY UNIVERSITY RESEARCH LABS, BY REGION, 2018-2024 (USD MILLION)
TABLE 190. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY UNIVERSITY RESEARCH LABS, BY REGION, 2025-2030 (USD MILLION)
TABLE 191. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, 2018-2024 (USD MILLION)
TABLE 192. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, 2025-2030 (USD MILLION)
TABLE 193. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 194. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 195. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY FISH, 2018-2024 (USD MILLION)
TABLE 196. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY FISH, 2025-2030 (USD MILLION)
TABLE 197. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY IHC, 2018-2024 (USD MILLION)
TABLE 198. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY IHC, 2025-2030 (USD MILLION)
TABLE 199. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAY, 2018-2024 (USD MILLION)
TABLE 200. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAY, 2025-2030 (USD MILLION)
TABLE 201. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 202. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 203. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY TARGETED SEQUENCING, 2018-2024 (USD MILLION)
TABLE 204. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY TARGETED SEQUENCING, 2025-2030 (USD MILLION)
TABLE 205. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY REAL TIME PCR, 2018-2024 (USD MILLION)
TABLE 206. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY REAL TIME PCR, 2025-2030 (USD MILLION)
TABLE 207. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 208. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 209. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2024 (USD MILLION)
TABLE 210. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, 2025-2030 (USD MILLION)
TABLE 211. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 212. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 213. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
TABLE 214. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2030 (USD MILLION)
TABLE 215. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 216. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 217. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 218. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 219. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY COLORECTAL CANCER, 2018-2024 (USD MILLION)
TABLE 220. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY COLORECTAL CANCER, 2025-2030 (USD MILLION)
TABLE 221. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 222. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 223. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 224. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 225. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 226. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 227. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
TABLE 228. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2030 (USD MILLION)
TABLE 229. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY HOSPITALS CLINICS, 2018-2024 (USD MILLION)
TABLE 230. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY HOSPITALS CLINICS, 2025-2030 (USD MILLION)
TABLE 231. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY PHARMA & BIOPHARMA COMPANIES, 2018-2024 (USD MILLION)
TABLE 232. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY PHARMA & BIOPHARMA COMPANIES, 2025-2030 (USD MILLION)
TABLE 233. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, 2018-2024 (USD MILLION)
TABLE 234. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, 2025-2030 (USD MILLION)
TABLE 235. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 236. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 237. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 238. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 239. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY FISH, 2018-2024 (USD MILLION)
TABLE 240. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY FISH, 2025-2030 (USD MILLION)
TABLE 241. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY IHC, 2018-2024 (USD MILLION)
TABLE 242. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY IHC, 2025-2030 (USD MILLION)
TABLE 243. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAY, 2018-2024 (USD MILLION)
TABLE 244. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAY, 2025-2030 (USD MILLION)
TABLE 245. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 246. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 247. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY TARGETED SEQUENCING, 2018-2024 (USD MILLION)
TABLE 248. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY TARGETED SEQUENCING, 2025-2030 (USD MILLION)
TABLE 249. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY REAL TIME PCR, 2018-2024 (USD MILLION)
TABLE 250. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY REAL TIME PCR, 2025-2030 (USD MILLION)
TABLE 251. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 252. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 253. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2024 (USD MILLION)
TABLE 254. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, 2025-2030 (USD MILLION)
TABLE 255. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 256. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 257. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
TABLE 258. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2030 (USD MILLION)
TABLE 259. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 260. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 261. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 262. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 263. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY COLORECTAL CANCER, 2018-2024 (USD MILLION)
TABLE 264. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY COLORECTAL CANCER, 2025-2030 (USD MILLION)
TABLE 265. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 266. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 267. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 268. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 269. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 270. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 271. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
TABLE 272. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2030 (USD MILLION)
TABLE 273. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY HOSPITALS CLINICS, 2018-2024 (USD MILLION)
TABLE 274. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY HOSPITALS CLINICS, 2025-2030 (USD MILLION)
TABLE 275. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY PHARMA & BIOPHARMA COMPANIES, 2018-2024 (USD MILLION)
TABLE 276. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY PHARMA & BIOPHARMA COMPANIES, 2025-2030 (USD MILLION)
TABLE 277. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, 2018-2024 (USD MILLION)
TABLE 278. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, 2025-2030 (USD MILLION)
TABLE 279. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 280. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 281. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 282. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 283. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY FISH, 2018-2024 (USD MILLION)
TABLE 284. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY FISH, 2025-2030 (USD MILLION)
TABLE 285. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY IHC, 2018-2024 (USD MILLION)
TABLE 286. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY IHC, 2025-2030 (USD MILLION)
TABLE 287. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAY, 2018-2024 (USD MILLION)
TABLE 288. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAY, 2025-2030 (USD MILLION)
TABLE 289. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 290. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 291. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY TARGETED SEQUENCING, 2018-2024 (USD MILLION)
TABLE 292. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY TARGETED SEQUENCING, 2025-2030 (USD MILLION)
TABLE 293. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY REAL TIME PCR, 2018-2024 (USD MILLION)
TABLE 294. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY REAL TIME PCR, 2025-2030 (USD MILLION)
TABLE 295. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 296. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 297. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2024 (USD MILLION)
TABLE 298. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, 2025-2030 (USD MILLION)
TABLE 299. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 300. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 301. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
TABLE 302. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2030 (USD MILLION)
TABLE 303. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 304. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 305. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 306. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 307. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY COLORECTAL CANCER, 2018-2024 (USD MILLION)
TABLE 308. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY COLORECTAL CANCER, 2025-2030 (USD MILLION)
TABLE 309. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 310. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 311. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 312. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Cancer/Tumor Profiling market report include:
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • F. Hoffmann-La Roche Ltd
  • QIAGEN N.V.
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • PerkinElmer, Inc.
  • Guardant Health, Inc.
  • Natera, Inc.
  • NeoGenomics, Inc.

Table Information

Report AttributeDetails
No. of Pages180
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 15.29 Billion
Forecasted Market Value ( USD ) by 2030 $ 36.01 Billion
Compound Annual Growth Rate18.8%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Cancer/Tumor Profiling Market Report Size, Share, Trends, and Forecast by Cancer Type, Technology, Technique, Application, and Region, 2025-2033 - Product Image

Cancer/Tumor Profiling Market Report Size, Share, Trends, and Forecast by Cancer Type, Technology, Technique, Application, and Region, 2025-2033

  • Report
  • 136 Pages
  • Global
From
Tumor Profiling Market Size, Share & Trends Analysis Report By Technique (Genomics, Proteomics), By Technology, By Application (Personalized Cancer Medicine), By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Tumor Profiling Market Size, Share & Trends Analysis Report By Technique (Genomics, Proteomics), By Technology, By Application (Personalized Cancer Medicine), By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 100 Pages
  • Global
From
Cancer Tumor Profiling Market Report 2025 - Product Image

Cancer Tumor Profiling Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Cancer/Tumor Profiling Market Size and Forecasts 2020-2031: Global and Regional Share, Trends, and Growth Opportunity Analysis by Technology, Application, and End-user - Product Image

Cancer/Tumor Profiling Market Size and Forecasts 2020-2031: Global and Regional Share, Trends, and Growth Opportunity Analysis by Technology, Application, and End-user

  • Report
  • 117 Pages
  • Global
From
Cancer / Tumor Profiling - Global Strategic Business Report - Product Image

Cancer / Tumor Profiling - Global Strategic Business Report

  • Report
  • 376 Pages
  • Global
From

About the Tumor Profiling Market

The Tumor Profiling market within the Diagnostics industry is a rapidly growing sector. It involves the use of advanced technologies such as next-generation sequencing (NGS) and polymerase chain reaction (PCR) to analyze the genetic makeup of tumors. This helps to identify the specific mutations that are driving the tumor's growth, allowing for more targeted treatments. Tumor profiling can also be used to monitor the effectiveness of treatments and to detect recurrence of the tumor. The market is driven by the increasing prevalence of cancer, the growing demand for personalized medicine, and the development of new technologies. Additionally, the increasing availability of genomic data and the development of artificial intelligence (AI) and machine learning (ML) are expected to further drive the market. Some of the major companies in the Tumor Profiling market include Illumina, Thermo Fisher Scientific, Agilent Technologies, QIAGEN, and Roche. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.